Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18660997 | AGENT FOR REDUCING VISCERAL FAT WEIGHT | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18423029 | METHODS FOR TREATING CHOLESTASIS | January 2024 | April 2025 | Allow | 15 | 3 | 0 | No | No |
| 18421934 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | January 2024 | December 2024 | Abandon | 11 | 1 | 1 | No | No |
| 18395982 | PYRAZINO[2',1':2,3]IMIDAZO[4,5-B][1,7]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORS | December 2023 | April 2024 | Allow | 4 | 1 | 1 | No | No |
| 18537765 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDER | December 2023 | March 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18515252 | CROMOLYN METAL COMPLEXES AS ENHANCED PHARMACEUTICAL FORMULATIONS AND METHOD OF USING THE SAME | November 2023 | March 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18502460 | ORGANIC COMPOUNDS | November 2023 | June 2025 | Allow | 19 | 2 | 0 | No | No |
| 18378976 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | October 2023 | March 2025 | Allow | 17 | 1 | 0 | No | No |
| 18482872 | REMEDIATION OF ALL DISEASES CAUSED BY RADIATION RELATED REACTIVE ION SPECIES ARE ALL CORRECTABLE BY H2S - SO2 GENERATED BY FDA-STS SODIUM THIOSULFATE, NA2S203 | October 2023 | May 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18363848 | SUSPENSION FOR ORAL ADMINISTRATION COMPRISING AMORPHOUS TOLVAPTAN | August 2023 | February 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18207668 | ADMINISTRATION OF N,N-DIMETHYLACETAMIDE AND ITS MONOMETHYLATED METABOLITES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | June 2023 | February 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18322909 | AGENT FOR REDUCING VISCERAL FAT WEIGHT | May 2023 | June 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18195921 | COMMIPHORA MYRRHA RESIN EXTRACT WITH NON-COVALENTLY ASSOCIATED VITAMIN B1 AND VITAMIN C COMPOUNDS | May 2023 | May 2025 | Abandon | 25 | 4 | 1 | No | No |
| 18137922 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | April 2023 | December 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 18137919 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | April 2023 | January 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18137925 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | April 2023 | December 2024 | Abandon | 20 | 1 | 1 | Yes | No |
| 17976710 | TREATMENT OF AUTOIMMUNE DISEASE | October 2022 | March 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18047932 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | October 2022 | November 2023 | Abandon | 13 | 2 | 0 | No | Yes |
| 17960669 | METHODS FOR TREATING CHOLESTASIS | October 2022 | November 2023 | Allow | 13 | 3 | 0 | Yes | No |
| 17937990 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | October 2022 | February 2023 | Allow | 4 | 1 | 0 | No | No |
| 17937994 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | October 2022 | May 2024 | Abandon | 19 | 3 | 0 | No | No |
| 17953036 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | September 2022 | December 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17902119 | AGENT FOR REDUCING VISCERAL FAT WEIGHT | September 2022 | July 2023 | Abandon | 10 | 1 | 0 | No | No |
| 17887270 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY | August 2022 | June 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17866724 | METHOD AND COMPOSITIONS FOR FORMING A COPPER-CONTAINING COMPLEX AND USES THEREOF | July 2022 | September 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17866514 | 3-TRIAZOLYL METHYL-1,3,5-TRIAZINE-2,4-DIONE COMPOUNDS AND PREPARATION METHOD AND APPLICATION THEREOF | July 2022 | December 2022 | Allow | 5 | 1 | 0 | No | No |
| 17866437 | ANTITHROMBOTIC COMPOSITIONS AND METHODS FOR USING SAME | July 2022 | April 2025 | Allow | 33 | 4 | 0 | No | No |
| 17860682 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | July 2022 | September 2022 | Allow | 3 | 1 | 0 | No | No |
| 17833131 | METHOD AND COMPOSITIONS FOR USE IN PROVIDING MALE CONTRACEPTION | June 2022 | April 2024 | Abandon | 22 | 3 | 1 | No | No |
| 17778369 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | May 2022 | March 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17717140 | USE OF POTASSIUM CHANNEL INHIBITOR FOR TREATING DEPRESSION | April 2022 | May 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17654061 | TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF | March 2022 | June 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17687929 | PHARMACEUTICAL COMPOSITION CONTAINING HDAC6 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF ITCHING | March 2022 | June 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17673136 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF INSOMNIA | February 2022 | June 2023 | Allow | 16 | 3 | 1 | Yes | No |
| 17572368 | AMINO ACID DELIVERY SYSTEM | January 2022 | March 2023 | Abandon | 14 | 2 | 0 | Yes | No |
| 17565584 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | December 2021 | July 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17554588 | METHODS FOR TREATING CHOLESTASIS | December 2021 | August 2022 | Allow | 8 | 2 | 0 | Yes | No |
| 17643145 | COMPOSITIONS FOR RETARDING THE DECOMPOSITION OF MELATONIN IN SOLUTION | December 2021 | July 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17519916 | STABLE CANNABINOID FORMULATIONS | November 2021 | February 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17607868 | Use of R-enantiomer Beta2-agonists for prevent and treatment of pulmonary inflammation and inflammatory remodeling for reduced adverse effects | October 2021 | July 2023 | Abandon | 21 | 2 | 0 | No | No |
| 17479382 | Crystalline Form of y-Aminobutyric Acid Analog | September 2021 | December 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17472882 | IDENTIFICATION OF AGENTS DISPLAYING FUNCTIONAL ACTIVATION OF DOPAMINE D2 AND D4 RECEPTORS | September 2021 | May 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17466366 | COMPOSITIONS COMPRISING FUSIDIC ACID AND PACKAGES THEREFOR | September 2021 | May 2023 | Abandon | 20 | 3 | 0 | No | No |
| 17375087 | Methods of Treating Ascites | July 2021 | August 2024 | Allow | 37 | 3 | 1 | No | No |
| 17353681 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | June 2021 | March 2023 | Allow | 21 | 1 | 0 | No | No |
| 17335407 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | June 2021 | October 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17320977 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAME | May 2021 | July 2023 | Allow | 27 | 1 | 0 | No | No |
| 17307208 | Cromolyn Metal Complexes as enhanced pharmaceutical formulations and method of preparing the same | May 2021 | August 2023 | Allow | 27 | 2 | 0 | No | No |
| 17244319 | Method of Treating Ascites | April 2021 | September 2022 | Abandon | 16 | 1 | 0 | No | No |
| 17238409 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | April 2021 | January 2023 | Allow | 21 | 1 | 0 | No | No |
| 17237137 | METHOD OF TREATING CANCER | April 2021 | February 2025 | Allow | 46 | 2 | 0 | No | No |
| 17232254 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | April 2021 | July 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17285432 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | April 2021 | August 2024 | Allow | 40 | 1 | 0 | No | No |
| 17226781 | COMPOSITION FOR BLOCKING ANGIOGENESIS | April 2021 | January 2023 | Allow | 22 | 0 | 1 | Yes | No |
| 17186651 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | February 2021 | October 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17186226 | AGENT FOR REDUCING VISCERAL FAT WEIGHT | February 2021 | October 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17268440 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | February 2021 | June 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17168291 | Arginase Inhibitors and Their Therapeutic Applications | February 2021 | March 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17164391 | 4-HYDROXYBUTYRIC ACID ANALOGS | February 2021 | September 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17137665 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | December 2020 | August 2023 | Allow | 31 | 2 | 0 | Yes | No |
| 17110398 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | December 2020 | November 2023 | Allow | 35 | 5 | 1 | No | No |
| 17100721 | Method to Identify Agents That Can Overcome Inhibition Caused By Drug-protein Binding of the Human Plasma Protein, Alpha-1-acid Glycoprotein | November 2020 | August 2023 | Abandon | 33 | 2 | 1 | No | No |
| 17055482 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | November 2020 | May 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17094405 | NOVEL PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MENOPAUSE RELATED ANXIETY AND DEPRESSION | November 2020 | October 2022 | Abandon | 24 | 3 | 1 | No | No |
| 17083783 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING RELAPSE IN A PERSON WITH AN ADDICTION USING BETA ADRENERGIC RECEPTOR ANTAGONIST AND MUSCARINIC RECEPTOR ANTAGONIST COMBINATIONS | October 2020 | June 2023 | Abandon | 32 | 1 | 1 | No | No |
| 17047479 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | October 2020 | September 2023 | Abandon | 35 | 0 | 1 | No | No |
| 17070401 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAME | October 2020 | March 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 17068552 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY | October 2020 | September 2022 | Abandon | 23 | 1 | 1 | No | No |
| 17066033 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | October 2020 | June 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17015883 | ORGANIC COMPOUNDS | September 2020 | August 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 17009457 | MELATONIN AGONIST TREATMENT | September 2020 | April 2022 | Abandon | 19 | 1 | 0 | No | No |
| 16994368 | METHODS FOR TREATING CHOLESTASIS | August 2020 | April 2021 | Allow | 8 | 4 | 1 | Yes | No |
| 16991726 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | August 2020 | May 2022 | Allow | 21 | 1 | 0 | No | No |
| 16943323 | METHOD OF TREATING CANCER | July 2020 | October 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16961302 | PHARMACEUTICAL COMPOSITION CONTAINING HDAC6 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF ITCHING | July 2020 | September 2022 | Abandon | 26 | 2 | 0 | Yes | No |
| 16924905 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | July 2020 | January 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 16913927 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | June 2020 | March 2022 | Allow | 21 | 5 | 1 | No | No |
| 16910786 | METHOD FOR TREATING PROTEIN AGGREGATION DISEASES | June 2020 | July 2022 | Abandon | 24 | 2 | 1 | No | No |
| 16956024 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | June 2020 | September 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16900498 | SALTS OF AN LSD1 INHIBITOR | June 2020 | July 2022 | Allow | 25 | 2 | 0 | No | No |
| 16899401 | USE OF A HETEROCYCLIC BCL-2 INHIBITOR FOR REMOVING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED CONDITIONS | June 2020 | February 2021 | Abandon | 8 | 0 | 1 | No | No |
| 16893012 | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions | June 2020 | January 2021 | Abandon | 8 | 0 | 1 | No | No |
| 16769892 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | June 2020 | May 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 16884459 | NOVEL PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANXIETY, DEPRESSION AND OTHER PSYCHIATRIC DISORDERS | May 2020 | January 2024 | Allow | 44 | 7 | 0 | Yes | No |
| 16884553 | NOVEL PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PSYCHIATRIC SYMPTOMS OF PATIENTS WITH ALZHEIMER'S DISEASE | May 2020 | November 2020 | Allow | 6 | 1 | 0 | No | No |
| 16766112 | SUBSTITUTED AZACYCLES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | May 2020 | September 2024 | Allow | 52 | 6 | 0 | Yes | No |
| 16875979 | COMPOSITIONS AND METHODS OF TREATING VIRAL INFECTIONS | May 2020 | July 2022 | Abandon | 26 | 2 | 0 | Yes | Yes |
| 15930583 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | May 2020 | December 2023 | Abandon | 43 | 2 | 1 | No | No |
| 16761631 | METHOD AND COMPOSITIONS FOR FORMING A COPPER-CONTAINING COMPLEX AND USES THEREOF | May 2020 | March 2022 | Allow | 23 | 4 | 1 | No | No |
| 16859275 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | April 2020 | June 2022 | Allow | 26 | 1 | 0 | No | No |
| 15733029 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | April 2020 | February 2022 | Abandon | 22 | 2 | 0 | No | No |
| 16855722 | AGENT FOR REDUCING VISCERAL FAT WEIGHT | April 2020 | April 2021 | Abandon | 12 | 1 | 0 | No | No |
| 16855385 | SCALP COOLING HAIR PRODUCT | April 2020 | November 2022 | Abandon | 31 | 2 | 0 | No | No |
| 16755631 | Use of System XC-Inhibitor for Treating Statin-Induced Myalgia | April 2020 | April 2023 | Abandon | 36 | 1 | 1 | No | No |
| 16844813 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | April 2020 | July 2021 | Allow | 15 | 1 | 1 | No | No |
| 16843416 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAME | April 2020 | September 2022 | Allow | 29 | 5 | 0 | Yes | No |
| 16813090 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | March 2020 | November 2020 | Abandon | 8 | 1 | 0 | No | No |
| 16791819 | METHODS FOR EVALUATING TREATMENTS AND PHYSIOLOGY IN HUMAN PATIENTS USING INTRAVENOUS ALPHA-2 ADRENERGIC ANTAGONIST AGENTS | February 2020 | February 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16784452 | COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF HEART FAILURE IN DOMESTIC ANIMALS | February 2020 | March 2024 | Allow | 50 | 5 | 1 | Yes | No |
| 16636299 | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells | February 2020 | February 2021 | Abandon | 12 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DRAPER, LESLIE A ROYDS.
With a 20.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 4.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DRAPER, LESLIE A ROYDS works in Art Unit 1629 and has examined 719 patent applications in our dataset. With an allowance rate of 26.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner DRAPER, LESLIE A ROYDS's allowance rate of 26.6% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DRAPER, LESLIE A ROYDS receive 2.44 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DRAPER, LESLIE A ROYDS is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.3% benefit to allowance rate for applications examined by DRAPER, LESLIE A ROYDS. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 9.4% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.2% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 12.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 22% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 52.9% of appeals filed. This is in the 19% percentile among all examiners. Of these withdrawals, 63.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 56.0% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.